RUNX1 Antibody, Biotin conjugated

Code CSB-PA020592LD01HU
Size US$299
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name Rabbit anti-Homo sapiens (Human) RUNX1 Polyclonal antibody
Uniprot No. Q01196
Target Names RUNX1
Alternative Names Acute myeloid leukemia 1 antibody; Acute myeloid leukemia 1 protein antibody; alpha subunit core binding factor antibody; AML 1 antibody; AML1 antibody; AML1 EVI 1 antibody; AML1 EVI 1 fusion protein antibody; Aml1 oncogene antibody; AMLCR 1 antibody; AMLCR1 antibody; CBF alpha 2 antibody; CBF-alpha-2 antibody; CBFA 2 antibody; CBFA2 antibody; Core binding factor alpha 2 subunit antibody; Core binding factor runt domain alpha subunit 2 antibody; Core-binding factor subunit alpha-2 antibody; EVI 1 antibody; EVI1 antibody; HGNC antibody; Oncogene AML 1 antibody; Oncogene AML-1 antibody; OTTHUMP00000108696 antibody; OTTHUMP00000108697 antibody; OTTHUMP00000108699 antibody; OTTHUMP00000108700 antibody; OTTHUMP00000108702 antibody; PEA2 alpha B antibody; PEA2-alpha B antibody; PEBP2 alpha B antibody; PEBP2-alpha B antibody; PEBP2A2 antibody; PEBP2aB antibody; Polyomavirus enhancer binding protein 2 alpha B subunit antibody; Polyomavirus enhancer-binding protein 2 alpha B subunit antibody; Run1 antibody; Runt related transcription factor 1 antibody; Runt-related transcription factor 1 antibody; RUNX 1 antibody; Runx1 antibody; RUNX1_HUMAN antibody; SL3 3 enhancer factor 1 alpha B subunit antibody; SL3-3 enhancer factor 1 alpha B subunit antibody; SL3/AKV core binding factor alpha B subunit antibody; SL3/AKV core-binding factor alpha B subunit antibody
Raised in Rabbit
Species Reactivity Human
Immunogen Recombinant Human Runt-related transcription factor 1 protein (211-445AA)
Immunogen Species Homo sapiens (Human)
Conjugate Biotin
Clonality Polyclonal
Isotype IgG
Purification Method >95%, Protein G purified
Concentration It differs from different batches. Please contact us to confirm it.
Buffer Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form Liquid
Tested Applications ELISA
Protocols ELISA Protocol
Troubleshooting and FAQs Antibody FAQs
Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Target Data

Function CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits KAT6B-dependent transcriptional activation. Controls the anergy and suppressive function of regulatory T-cells (Treg) by associating with FOXP3. Activates the expression of IL2 and IFNG and down-regulates the expression of TNFRSF18, IL2RA and CTLA4, in conventional T-cells
Gene References into Functions
  1. In this study, the presence of clonal heterogeneity and impaired FCM-MRD clearance among ETV6/RUNX1-positive patients, ultimately influenced prognosis. PMID: 29778230
  2. Results show that Runx1 associates with c-Abl kinase through its C-terminal inhibitory domain which directly binds to c-Abl. Also, Runx1 is phosphorylated by c-Abl kinase modulating its transcriptional activity and megakaryocyte maturation. PMID: 29730354
  3. DEGs and pathways identified in the present study will help understand the molecular mechanisms underlying RUNX1 mutations in AML and develop effective therapeutic strategies for RUNX1-mutation AML. PMID: 30289875
  4. RUNX1 regulates ITGA6 through a consensus RUNX1 binding motif in its promoter PMID: 28926098
  5. Loss of RUNX1 resulted in enhanced proliferation, migration, and invasion of lung adenocarcinomas PMID: 28926105
  6. Ezh2 and Runx1 mutations collaborate to initiate lympho-myeloid leukemia in early thymic progenitors PMID: 29438697
  7. miR-144 mimics can inhibit the proliferation and migration of ovarian cancer cells though regulating the expression of RUNX1. PMID: 29445078
  8. The effect of FENDRR on cell proliferation, apoptosis and invasion and migration ability in protate cancer cells was suppressed by silence of RUNX1. PMID: 29465000
  9. KSRP, miR-129, and RUNX1 participate in a regulatory axis to control the outcome of myeloid differentiation. PMID: 29127290
  10. PKM2 as a novel target of RUNX1-ETO and is specifically downregulated in RUNX1-ETO positive AML patients, indicating that PKM2 level might have a diagnostic potential in RUNX1-ETO associated AML. PMID: 28092997
  11. specific type of RUNX1 mutation did not affect its association pattern with trisomy 21 PMID: 29249799
  12. High RUNX1 expression is associated with prostatic cancer. PMID: 29328406
  13. RUNX1 Mutation is associated with acute myeloid leukemia. PMID: 29479958
  14. The specific association of ZBTB7A mutations with t(8;21) rearranged acute myeloid leukaemia points towards leukemogenic cooperativity between mutant ZBTB7A and the RUNX1/RUNX1T1 fusion protein has been reported. PMID: 27252013
  15. miR-216a-3p can promote gastric cancer cell proliferation, migration, and invasion via targeting RUNX1 and activating the NF-kappaB signaling pathway PMID: 28835317
  16. the t(5;21)(p15;q22) translocation could be identified only when what had seemed like a del(21)(qq) in G-banded preparations was examined using FISH and RNA-sequencing directed at finding out what lay behind the 21q-. PMID: 29672642
  17. Our findings show the profound impact of RUNX1 allele dosage on gene expression profile and glucocorticoid sensitivity in AML, thereby opening opportunities for preclinical testing which may lead to drug repurposing and improved disease characterization. PMID: 28855357
  18. This study established inducible RUNX1b/c-overexpressing human embryonic stem cell (hESC) lines, in which RUNX1b/c overexpression prevented the emergence of CD34+ cells from early stage, thereby drastically reducing the production of hematopoietic stem/progenitor cells. Simultaneously, the expression of hematopoiesis-related factors was downregulated. PMID: 28992293
  19. Genome-engineered hPSCs expressing ETV6-RUNX1 from the endogenous ETV6 locus show expansion of the CD19(-)IL-7R(+) compartment PMID: 29290585
  20. our study demonstrated that specific bone marrow abnormalities and acquired genetic alterations may be harbingers of progression to hematological malignancies in patients with familial platelet disorder with germline RUNX1 mutation. PMID: 28659335
  21. These studies provide the first evidence in patients with a RUNX1 mutation for a defect in AH (lysosomal) secretion, and for a global defect in secretion involving all three types of platelet granules that is unrelated to a granule content deficiency. They highlight the pleiotropic effects and multiple platelet defects associated with RUNX1 mutations. PMID: 28662545
  22. Younger mRUNX1 AML patients treated with intensive chemotherapy experienced inferior treatment outcomes. In older patients with AML treated with hypomethylating agent (HMA) therapy, response and survival was independent of RUNX1 status. Older mRUNX1 patients with prior myelodysplastic syndrome or myeloproliferative neoplasms (MDS/MPN) had particularly dismal outcome PMID: 28933735
  23. Data indicate miR-29b-1 as a regulator of the AML1-ETO protein (RUNX1-RUNX1T1), and that miR-29b-1 expression in t(8;21)-carrying leukemic cell lines partially rescues the leukemic phenotype. PMID: 28611288
  24. EBPA and RUNX1 are expressed at higher levels in patients with acute myeloid leukemia in comparison to healthy subjects PMID: 28895127
  25. The first characterization of this CASC15 in RUNX1-translocated leukemia. PMID: 28724437
  26. Altogether, these results revealed an unexpected and important epigenetic mini-circuit of AML1-ETO/THAP10/miR-383 in t(8;21) acute myeloid leukaemia, in which epigenetic suppression of THAP10 predicts a poor clinical outcome and represents a novel therapeutic target. PMID: 28539478
  27. Several studies addressed the mechanism by which ETV6/RUNX1 (E/R) contributes to leukemogenesis, including the necessary secondary genetic lesions, the cellular framework in which E/R initially arises and the maintenance of a pre-leukemic condition. [review] PMID: 28418909
  28. MLD- and MLD+ RUNX1-mutated AML differ in some associations to genetic markers, such as +13 or IDH2 mutation status without prognostic impact in multivariate analysis. However, in RUNX1-mutated AML, the overall pattern shows a specific landscape with high incidences of trisomies (such as +8 and +13), and mutations in the spliceosome and in chromatin modifiers PMID: 27211269
  29. RUNX1-RUNX1T1 transcript levels were measured in bone marrow samples collected from 208 patients at scheduled time points after transplantation.Over 90% of the 175 patients who were in continuous complete remission had a >/=3-log reduction in RUNX1-RUNX1T1 transcript levels from the time of diagnosis at each time point after transplantation and a >/=4-log reduction at >/=12 months. PMID: 28166825
  30. RUNX1 defects causing haploinsufficiency are thought to be associated with a lower incidence of myeloid malignancies when compared to those patients with dominant-negative RUNX1 defects. PMID: 28277065
  31. This result suggests that TET2(P1962T) mutation in association with germline RUNX1(R174Q) mutation leads to amplification of a haematopoietic clone susceptible to acquire other transforming alterations PMID: 27997762
  32. Presence of fusion the genes BCR/ABL1, ETV6/RUNX1, and MLL/AF4 does not have any impact on the clinical and laboratory features of ALL at presentation. PMID: 26856288
  33. ETV6/RUNX1 (+) ALL may be heterogeneous in terms of prognosis, and variables such as MRD at end ofremission induction or additional structural abnormalities of 12p could define a subset of patients who are likely to have poor outcome. PMID: 27506214
  34. High RUNX1 expression is associated with lymphoma. PMID: 27056890
  35. PLDN is a direct target of RUNX1 and its dysregulation is a mechanism for platelet dense granule deficiency associated with RUNX1 haplodeficiency PMID: 28075530
  36. The here presented transcriptomic subgroup-based approach unified the gene expression profiles of RUNX1-CBFA2T3 and RUNX1-RUNX1T1 acute myeloid leukemia. PMID: 26968532
  37. Platelet CD34 expression and alpha/delta-granule abnormalities in GFI1B- and RUNX1-related familial bleeding disorders. PMID: 28096094
  38. We observed a strong correlation between EVI1 and alpha1, 6-fucosyltransferase (FUT8) in the chronic phase of the disease and both of them were found to be up-regulated with the progression of the disease. PMID: 27967290
  39. A novel function of RUNX1 and offer an explanation for the link between RUNX1 mutations and chemotherapy and radiation resistance. Moreover, these data suggest that pharmacologic modulation of RUNX1 might be an attractive new approach to treat hematologic malignancies. PMID: 29055018
  40. high EVI1 expression might predict high risk of relapse in AML patients undergoing myeloablative allo-HSCT in CR1. PMID: 27042849
  41. Hypermethylation of the CTNNA1 promoter was associated with unfavorable karyotype, and possessed the higher frequency of coexisting with ASXL1 and RUNX1 mutations. PMID: 27129146
  42. Three siblings with germline causative RUNX1 variant, developed acute myelomonocytic leukemia and acquired variants within the JAK-STAT pathway, specifically targeting JAK2 and SH2B3. PMID: 28513614
  43. These findings suggest RUNX1high is a prognostic biomarker of unfavorable outcome in cytogenetically normal acute myeloid leukemia PMID: 26910834
  44. 3 di ff erent heterozygous mutations segregated with thrombocytopenia in 3 families: one missense (c.578T > A/p.Ile193Asn) variant a ff ecting a well conserved residue of the runt-homologous domain, 2 nucleotide substitutions of the canonical "gt" dinucleotide in the donor splice sites of intron 4, (c.351 1 1G > A) and intron 8 (c.967 1 2_5del), and 2 alternative spliced products affecting the transactivation domain. PMID: 28240786
  45. Here, we report the first identification of H3(K27M) and H3(K27I) mutations in patients with AML. We find that these lesions are major determinants of reduced H3K27me2/3 in these patients and that they are associated with common aberrations in the RUNX1 gene. PMID: 28855157
  46. NPM1 mutation but not RUNX1 mutation or multilineage dysplasia defines a prognostic subgroup within de novo acute myeloid leukemia lacking recurrent cytogenetic abnormalities PMID: 28370403
  47. phenotype and bleeding risks of an inherited platelet disorder in a family with a RUNX1 frameshift mutation PMID: 28181366
  48. ERG, FLI1, TAL1, and RUNX1 bind at all AML1-ETO-occupied regulatory regions, including those of the AML1-ETO gene itself, suggesting their involvement in regulating AML1-ETO expression levels. PMID: 27851970
  49. Our work sheds light on the role of RUNX1 and the importance of dosage balance in the development of neural phenotypes in DS. PMID: 27618722
  50. Studies showed a transient expression of RUNX1 during early mesendodermal differentiation of hESCs suggesting it contribution to differentiation in addition to the hematopoietic lineage identity. RUNX1 has a defined role in the epithelial to mesenchymal transition, and the associated competency for cell mobility and motility required for development of the mesendodermal germ layer. [review] PMID: 27591551
  51. discussion of the role of RUNX1 in diseases caused by their mutations or deletions (review) PMID: 28299663
  52. Placental hematopoietic stem and progenitor cells likely arise from hematopoietic niches comprised RUNX1+ mesenchyme and vascular endothelium. Pregnancy complications that result in preterm birth differentially affect placental hematopoietic stem and progenitor cells localization and RUNX1 expression PMID: 26944948
  53. deficiency alters the expression of a crucial subset of TAL1- and NOTCH1-regulated genes, including the MYB and MYC oncogenes, respectively. PMID: 28790107
  54. Our findings strengthen previous data concerning RUNX1 mutations in acute myeloid leukemia and support the notion that RUNX1 mutational status should be integrated into a diagnostic workup of acute myeloid leukemia. PMID: 28927163
  55. Heterozygous germ line mutations in the RUNX1 gene are responsible genetic events for FPD/AML. PMID: 28534116
  56. Data suggest that RUNX1 pays dual roles in normal female sexual development/maturation and tumorigenesis in female-related cancers; "alterations" in RUNX1, either mutations in RUNX1 gene or variations in expression of RUNX1, appear to be associated with breast, ovarian, uterine, and cervical neoplasms. [REVIEW] PMID: 28304148
  57. The E3 ubiquitin ligase STUB1 is a negative regulator of both RUNX1 and RUNX1-RUNX1T1. Activation of STUB1 could be a promising therapeutic strategy for RUNX1-RUNX1T1 leukemia. PMID: 28536267
  58. The clinical significance of ETV6-RUNX1. PMID: 28299659
  59. Deliver the necessary promotional drive for the progression of ETV6-RUNX1+ pre-leukaemic cells. PMID: 28299660
  60. High RUNX1 expression is associated with pancreatic cancer. PMID: 27617577
  61. these findings have identified a novel function for Runx1 in sustaining normal mammary epithelial morphology and preventing epithelial-mesenchymal transition PMID: 28407681
  62. Leukaemogenesis by AML1-ETO requires enhanced C/D box snoRNA/RNP formation. PMID: 28650479
  63. In this study, we found upregulation of several hemostasis-related genes, including the thrombin-activatable receptor PAR-1 (protease-activated receptor-1), in Runx1/Cbfb-deleted MLL-AF9 cells. Similar to the effect of Runx1/Cbfb deletion, PAR-1 overexpression induced CDKN1A/p21 expression and attenuated proliferation in MLL-AF9 cells PMID: 27819671
  64. LRG1 plays a crucial role in the proliferation and apoptosis of colorectal cancer (CRC) by regulating RUNX1 expression. PMID: 28376129
  65. RUNX1 RNA and protein are upregulated in proliferative diabetic retinopathy and in response to high glucose in vitro. Immunohistochemical staining for RUNX1 showed reactivity in vessels of patient-derived fibrovascular membranes, suggesting that RUNX1 upregulation is a hallmark of aberrant retinal angiogenesis. PMID: 28400392
  66. RUNX1 overexpression induced partial DNA demethylation at SPI1 proximal promoter. PMID: 28376714
  67. mutations in the SRSF2/ASXL1/RUNX1 gene panel identified as significant prognostic markers in systemic mastocytosis PMID: 27416984
  68. HHEX could replace RUNX1 in cooperating with FLT3-ITD to induce Acute myeloid leukemia (AML). PMID: 28213513
  69. RUNX1-mutated AML is associated with a complex mutation cluster and is correlated with distinct clinico-pathologic features and inferior prognosis. PMID: 27137476
  70. It was found that the absence of mutations in the SRSF2, ASXL1, and/or RUNX1gene panel at baseline and a reduction of the KIT D816V allele burden more than 25% at month 6 are the most favorable predictors for improved survival in midostaurin-treated advanced systemic mastocytosis patients. PMID: 28424161
  71. Our findings suggest ETV6-RUNX1 is associated with space-time clustering of childhood leukemia (CL) and are consistent with an infection interacting with that oncogene in early life leading to clinical leukemia. PMID: 28129329
  72. Mutation in RUNX1 gene is associated with chronic myelomonocytic leukemia. PMID: 27385790
  73. RUNX1-RUNX1T1 fusion is associated with acute myeloid leukemia. PMID: 28063196
  74. Study demonstrated that TRiC's contribution to the activity of the DNA-binding domain (AML1-175) of AML1-ETO is consistent with its contribution to the activity of full-length AML1-ETO and is mediated through its direct association with the DNA-binding domain PMID: 27276256
  75. results provide novel insight into RUNX1-mediated perturbations of higher-order genome organization that are functionally linked with RUNX1-dependent compromised gene expression in breast cancer cells PMID: 27514584
  76. RUNX1 and AXIN1 proteins are strongly correlated in ER(-) tumors as well. PMID: 28055379
  77. he data suggest a central role for RUNX1 as master regulator of gene expression in the U87 glioblastoma multiforme cell line and mark RUNX1 as a potential target for novel future therapies for glioblastoma multiforme PMID: 28443460
  78. Study highlights the importance of interactions among lncRNA HCP5, microRNA-139, and transcription factor RUNX1 in regulating the malignant behavior of glioma cells. HCP5 down-regulated miR-139 to up-regulate RUNX1. RUNX1 promoted AEG-1 expression, which was involved in a series of oncogenic effects in glioma cells. RUNX1 also up-regulated HCP5 expression, which formed a positive feedback loop. PMID: 27434586
  79. Data suggest that RUNX1 functions in stem cells regulating cell differentiation; cancer cells appear to have corrupted this function of RUNX1 into promotion of oncogenesis. [REVIEW] PMID: 28490659
  80. the AML1-ETO fusion protein increases the expression of SIRT1, possibly by binding to the promoter region of SIRT1 to activate its transcription in t(8;21) AML. PMID: 27725192
  81. the Notch pathway DNA-binding protein RBP-J is the key cellular factor hijacked by EBNA2 to direct activation of RUNX1 transcription via upstream super-enhancers. PMID: 26883634
  82. revealed more than 170 NFAT-associated proteins, half of which are involved in transcriptional regulation. Among them are many hitherto unknown interaction partners of NFATc1 and NFATc2 in T cells, such as Raptor, CHEK1, CREB1, RUNX1, SATB1, Ikaros, and Helios. PMID: 27637333
  83. Data show that the interaction between aptamer and AML1 (RUNX1) protein DNA-binding domain known as the Runt domain (RD) is driven by a large enthalpy change. PMID: 27766833
  84. A feedback circuitry involving miR-9-1 and RUNX1-RUNX1T1. PMID: 27770540
  85. The requirement for Runx1 in the normal hematopoietic development and its dysregulation through chromosomal translocations and loss-of-function mutations as found in acute myeloid leukemias highlight the importance of this transcription factor in the healthy blood system. PMID: 28179276
  86. RUNX1 is one of the most frequently mutated genes in a variety of hematological malignancies. Germ line mutations in RUNX1 cause familial platelet disorder with associated myeloid malignancies. PMID: 28179279
  87. In the PPI network, genes may be involved in Down syndrome (DS) by interacting with others, including nuclear receptor subfamily 4 group A member 2 (NR4A2)early growth response (EGR)2 and NR4A2EGR3. Therefore, RUNX1, NR4A2, EGR2, EGR3 and ID4 may be key genes associated with the pathogenesis of DS. PMID: 27667480
  88. Study shows that AML1 gene overexpression characterizes a broader range of leukemic subtypes than previously thought, including various maturation stages of B-cell acute lymphoblastic leukemia and cytogenetic types additional to those involving the AML1 gene. PMID: 28349830
  89. the effects of various aberrations in ETV6 and RUNX1 gene copy number on disease prognosis were evaluated in 21 pediatric patients diagnosed with B-cell ALL with/without t(12;21). PMID: 27393278
  90. The RUNX1 fusion transcript encodes a truncated protein containing the Runt homology domain responsible for both heterodimerization with CBFB and DNA binding, but lacking the proline-, serine-, and threonine-rich (PST) region which is the transcription activation domain at the C terminal end PMID: 27667292
  91. novel RUNX1 isoforms contribute in controlling CD56 expression in acute myeloid leukemia cells. PMID: 26706848
  92. this paper shows that RUNX1 is associated with the pathogenesis of immune thrombocytopenia possibly through regulation of Th17 cell differentiation PMID: 27288310
  93. We show that RUNX1 P1 expression is associated with colon cancer free survival suggesting a role for RUNX1 in aspirin's protective effect in colon cancer. Our studies reveal an effect of aspirin on RUNX1 and gene expression that may additionally explain aspirin's effects in cardiovascular disease and cancer. PMID: 27566955
  94. we identified rs2249650 and rs2268276 as new AML susceptibility-associated SNPs. Genome editing at rs2249650 and rs2268276 may be performed in future to uncover the effect of this potential RUNX1 enhancer region. PMID: 26374622
  95. RUNX1 and FKBP7, involved in erythropoesis and muscle protein synthesis, respectively, are related to change in cardiorespiratory fitness in response to exercise. PMID: 23899896
  96. HTLF is a RUNX1 target whose down-regulation promotes genomic instability and correlates with complex cytogenetic abnormalities in acute myeloid leukemia patients. PMID: 26802049
  97. High RUNX1 expression is associated with breast cancer. PMID: 26735887
  98. The Leukemia Inhibitory Factor Receptor Gene Is a Direct Target of RUNX1 PMID: 26060100
  99. the tumor-suppressor runt domain transcription factor 1 (RUNX1) was confirmed to be a downstream molecule of H19/miR-675 axis, since overexpression of H19 or miR-675 significantly decreased RUNX1 expression in Gastric Cancer cells PMID: 26931432
  100. Low expression of RUNX1 is associated with malignant progression of gastric cancer. PMID: 26716895

Show More

Hide All

Involvement in disease Familial platelet disorder with associated myeloid malignancy (FPDMM)
Subcellular Location Nucleus
Tissue Specificity Expressed in all tissues examined except brain and heart. Highest levels in thymus, bone marrow and peripheral blood.
Database Links

HGNC: 10471

OMIM: 151385

KEGG: hsa:861

STRING: 9606.ENSP00000300305

UniGene: Hs.149261

Most popular with customers


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1